Sierra Oncology Announces Completion of Enrollment for MOMENTUM Phase 3 Trial

SAN MATEO, Calif.: —Topline data anticipated in Q1 2022 with NDA filing to follow in H2 2022— SAN MATEO, Calif., June 21, 2021 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced the...

Click to view original post